ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
An affiliate of contract research and manufacturing firm WuXi AppTec has registered with the U.S. Securities & Exchange Commission for a fund that will invest up to $250 million in the life sciences sector. The investment vehicle, WuXi Healthcare Ventures Fund II, would buy “significant equity stakes” in companies in the U.S. and China. The firm made a similar move in 2011, when it launched its self-funded $50 million WuXi Venture Fund. By year-end 2014, the fund had invested $36 million in 18 companies. WuXi says it made money on its investment and was able to market its services to the firms. Separately, WuXi has raised $80 million by selling 6% of its custom manufacturing subsidiary SynTheAll Pharmaceutical to 33 institutional investors in China. This is becoming a landmark year for WuXi, China’s largest chemistry-oriented contract research firm. In April, the company received an offer from its founder Ge Li and a consortium to take the firm private by delisting from the New York Stock Exchange. And in May, WuXi said it was buying, along with other Chinese companies, the California-based biotechnology firm Ambrx.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X